
    
      This study is designed to provide efficacy data in support of the proposed claims of reducing
      signs and symptoms, improvement in physical function, and 1 year safety data for KN019 dosed
      at 5 and 10 mg/kg in patients with inadequate response to stable weekly doses of background
      methotrexate.
    
  